摘要
目的：探讨甲硝唑致心脏损害的特点和规律,为临床安全用药提供参考。方法：采用回顾性研究方法,对河南省药品不良反应（ADR）监测中心2010年1月-2015年12月收到的58例甲硝唑致心脏损害的报告进行分析。结果：58例甲硝唑致心脏损害病例中,男性25例,女性33例,男女比例为0.76∶1;发生ADR/药品不良事件（ADE）患者年龄以15~64岁为主（74.14%）;静脉给药途径最多见（79.31%）;发生在30 min内居多（70.69%）;主要表现为心悸,严重者可致心动过速和心律失常;58例患者经停药或对症治疗后ADR均好转或痊愈。结论：临床应加强对甲硝唑致ADR/ADE的观察,特别是对心脏毒性反应的监测;药品生产企业应完善药品说明书,以确保临床用药的安全。
OBJECTIVE：To explore the characteristics and regularities of cardiac damage induced by metranidazole,and provide reference for clinical safe application. METHODS：In retrospective study,58 cases of cardiac damage caused by metranidazole in Henan ADR Monitoring Center for Drug from Jan. 2010 to Dec. 2015 were analyzed statistically. RESULTS：In 58 cases of cardiac damage induced by metranidazole,25 cases were male,33 were female,the ratio of male to female was 0.76∶1,the patients with ADR/ADE aged 15-64 years（74.14%）,most were intravenous administration（79.31%）and happened within 30 min（70.69%）,cardiac damage mainly manifested as palpitation,severe cases can cause tachycardia and arrhythmia,the ADR improved or cured after withdrawal or symptomatic treatment. CONCLUSIONS：Clinic should strengthen observation of ADR/ADE caused by metranidazole,especially the monitoring of cardiac toxicity reactions;pharmaceutical manufacturers should improve the drug instructions to insure the safety of clinical medication.
出处
《中国药房》
CAS
北大核心
2016年第26期3643-3645,共3页
China Pharmacy
关键词
甲硝唑
心脏损害
药品不良反应/事件
分析
Metranidazole
Cardiac damage
Adverse drug reaction/event
Analysis
